| Property | Value |
|----------|-------|
| Category | Protein Biomarker / Therapeutic Target |
| Target | Progranulin protein (granulin peptides) |
| Sample Type | CSF, plasma, serum |
| Diseases | Frontotemporal Dementia, ALS, Alzheimer's Disease, Parkinson's Disease |
| Clinical Use | Diagnosis, disease progression, treatment monitoring |
Progranulin (PGRN) is a secreted growth factor-like protein that plays important roles in neuronal survival, synaptic function, and inflammation. It is encoded by the GRN gene and is particularly important in frontotemporal dementia (FTD) where GRN mutations cause haploinsufficiency. Both the protein itself and its cleaved fragments (granulins) serve as biomarkers and therapeutic targets.
¶ Gene and Protein
- Gene: GRN (Progranulin) located on chromosome 17q21.31
- Protein: Progranulin, 593 amino acids (~63 kDa)
- Structure: Contains 7.5 tandem granulin repeats
- Cleavage: Secreted as full-length protein, cleaved by proteases (elastase, MMP-9)
- Neuronal survival: Neurotrophic factor for neurons
- Synaptic plasticity: Regulates glutamatergic transmission
- Inflammation: Modulates microglial activation
- Wound healing: Growth factor activity
- Lysosomal function: Critical for autophagosome-lysosome fusion
- Commercial kits available (R&D Systems, Adipogen)
- Measures total progranulin (full-length + fragments)
- Plasma: 20-50 ng/mL in healthy controls
- CSF: 1-5 ng/mL (lower than plasma)
- Ultra-sensitive for low CSF concentrations
- Can detect early changes in pre-symptomatic carriers
- GRN mutations: Haploinsufficiency causes FTD
- C9orf72: Can be comorbid with GRN mutations
- Predictive testing: Identifies at-risk individuals
- GRN mutation carriers: 50% reduction in plasma progranulin
- Diagnostic utility: Helps distinguish from Alzheimer's disease
- Disease progression: Levels correlate with clinical decline
- Pre-symptomatic: Changes detectable years before onset
- Reduced progranulin in some ALS patients
- May correlate with disease severity
- Therapeutic target for enhancement
- Variable results in AD patients
- May be elevated in some subtypes
- Ongoing research for biomarker utility
- Some studies show altered levels
- May reflect neuroinflammation
| Metric |
GRN(+) FTD vs Controls |
GRN(+) vs GRN(-) FTD |
| Sensitivity |
75-85% |
80-90% |
| Specificity |
85-95% |
70-80% |
| AUC |
0.82-0.90 |
0.78-0.86 |
- Progranulin levels inversely correlate with disease severity in FTD
- Faster progression in carriers with lowest levels
- Levels predict age of onset within mutation carriers
| Biomarker |
FTD Utility |
Specimen |
AUC |
| Progranulin |
Primary |
Plasma/CSF |
0.82-0.90 |
| NfL |
Secondary |
CSF/Plasma |
0.85-0.92 |
| p-Tau181 |
Differential |
CSF |
0.75-0.85 |
| TDP-43 |
Pathology |
CSF |
0.78-0.88 |
- J-ADNI and Japanese FTD registries show similar progranulin reductions in GRN carriers
- Plasma progranulin cutoffs: <20 ng/mL for Japanese populations
- Specific reference ranges established for Asian populations
- Korean FTD patients show comparable patterns
- GRN mutation frequency similar to Western populations
- Ongoing studies in Korean clinical centers
- Chinese Alzheimer's Association and CANDI cohort data available
- Population-specific reference ranges under development
- Cross-ethnic validity studies ongoing
| Biomarker |
Specimen |
Utility |
| Progranulin |
Plasma |
Primary - identifies GRN carriers |
| NfL |
Plasma/CSF |
Disease burden |
| p-Tau181 |
CSF |
AD differential |
| TDP-43 |
CSF |
pathology marker |
- Combined panel (progranulin + NfL): AUC 0.88-0.93
- Adds predictive value for disease progression
- Helps distinguish FTD subtypes
- FDA: No FDA-cleared progranulin assay currently
- Laboratory-developed tests (LDTs) available in specialized labs
- CMS coverage: Limited to research use
- CE-IVD标记: No CE-cleared progranulin assay
- Available in specialized European reference labs
- IVDR compliance in progress for new assays
- PMDA (Japan): No approved assay
- NMPA (China): Under development
- KFDA (Korea): Research use only
| Test Type |
Cost Range |
Turnaround |
| Plasma ELISA |
$50-100 |
1-3 days |
| Simoa (ultrasensitive) |
$150-250 |
3-5 days |
| CSF ELISA |
$75-125 |
1-3 days |
| Genetic testing |
$300-500 |
2-4 weeks |
| Full biomarker panel |
$400-800 |
5-7 days |
- Progranulin testing cost-effective for FTD families
- Enables predictive testing in at-risk individuals
- Guides therapeutic decisions
- Plasma: EDTA tube, centrifuge within 1 hour
- CSF: LP procedure, store at -80°C
- Fasting state may affect levels
- Age: Slight decrease with age
- Sex: No significant differences
- Kidney function: May affect clearance
- Inflammation: Acute changes
- Plasma: 24 hours at room temperature
- CSF: 1 week at 4°C,长期存储 at -80°C
- Freeze-thaw: Up to 3 cycles acceptable
- ** haploinsufficiency**: Loss-of-function mutations reduce protein by 50%
- Lysosomal dysfunction: PGRN crucial for lysosomal function
- TDP-43 pathology: 70% of FTD-GRN cases have TDP-43 inclusions
- Microglial activation: Altered neuroimmune response
- Neuronal vulnerability: Reduced neurotrophic support
- Progranulin may be neuroprotective
- Some mutations associated with ALS-FTD spectrum
- Levels may reflect disease activity
- AAV-mediated delivery in development
- Recombinant protein therapy
- Small molecule enhancers
- AAV vectors for GRN delivery
- CRISPR-based approaches
- Antisense oligonucleotides
- Arimoclomol: Heat shock protein co-inducer (in trials)
- Autophagy enhancers: Increase endogenous PGRN
- Proteostasis modulators: Improve folding/secretion
The study of Progranulin (Pgrn) Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Variable levels: Significant inter-individual variation
- Not disease-specific: Altered in multiple conditions
- Assay differences: ELISA kits give different values
- Sample handling: Requires careful processing
- Therapeutic context: Some treatments may affect levels